Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Proof-of-Concept Study of CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism

Next Previous
X
Search
Trial Profile

A Phase 2 Proof-of-Concept Study of CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors XERIS Pharmaceuticals

    • Most Recent Events

    • 09 May 2019 According to a Xeris Pharmaceuticals media release, data from this trial were presented at the ENDO 2019 in March.
    • 08 Nov 2018 Status changed from recruiting to completed.
    • 14 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top